Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection

Pediatrics

Volumn 99, Issue 4, 1997, Pages 575-580

  King Jr , James C ^a   Vink, Peter E ^a   Farley, John J ^a   Smilie, Martha ^a   Parks, Marie ^a   Lichenstein, Richard ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

human immunodeficiency virus; pneumococcus; Streptococcus pneumoniae; vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 0030900795     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.99.4.575     Document Type: Article

References (22)

1. Farley JJ, King JC, Nair P, Hines SE, Tressler RL, Vink PE. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr. 1994;124: 853-858
2. Andiman WA, Mezger J, Shapiro E. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. J Pediatr. 1994;124:846-852
3. Peters VB, Hyatt AC, Diamant EP, Hodes DS. Evaluation of prophylaxis against invasive pneumococcal infections in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1994;13:667-669
4. Committee on Infectious Diseases, American Academy of Pediatrics. Pneumococcal infections. In: Peter G, ed. Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1994:371-375
5. Douglas RM, Paton JC, Duncan SJ, Hausman DJ. Antibody responses to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983;148:131-137
6. King JC Jr, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1996;15:192-196
7. Arpadi SM, Back S, O'Brien J, Janoff EN. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. J Pediatr. 1994; 125:77-79
8. Klein DL. Pneumococcal conjugate vaccines: review and update. Microb Drug Resistance - Mechanisms Epidemiol Dis. 1995;1:49-58
9. Ahman H, Kayhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J. 1996;15:134-139
10. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR. 1994;43(RR-12):1-10
11. Quataert SA, Kirch CS, Quackenbush Wiedl LJ, et al. Assignment of weight-based antibody units to a human anti-pneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995;2:590-597
12. Keuls M. The use of the "studentized range" in connection with analysis of variance. Euphytics. 1952;1:112-122
13. Black SB, Shinefield HR, Lampert D, et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. Pediatr Infect Dis J. 1991;10:92-96
14. Centers for Disease Control and Prevention. Pneumococcal polysaccharide vaccine. MMWR. 1989;38:64-68,73-76
15. Paradiso PR, Hogerman DA, Madore DV, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccine in young infants. Pediatrics. 1993;92:827-832
16. Kale KL, King JC, Farley JJ et al. The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants. Pediatr Infect Dis J. 1995; 14:350-354
17. Brẽna AE, Cooper ER, Cabral HJ, Pelton SI. Antibody response to measles and rubella vaccine by children with HIV infection. J Acquired Immune Defic Syndr. 1993;6:1125-1129
18. Landesman SH, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high risk populations. Rev Infect Dis. 1981;3: S184-S196
19. Koskela M. Serum antibodies to pneumococcal C polysaccharide in children: response to acute otitis media or to vaccination. Pediatr Infect Dis J. 1987;6:519-526
20. Marty GV, Rubin LG. Human anti-capsular antibody concentration required for protection against experimental pneumococcal bacteremia. Presented at the 64th Society for Pediatric Research Meeting; May 9, 1995; San Diego, CA
21. Giebink GS, Koskela M, Vella PP, Harris M, Le C. Pneumococcal capsular polysaccharide meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis. 1993;167:347-355
22. Orange M, Gray BM. Pneumococcal serotypes causing disease in children in Alabama. Pediatr Infect Dis J. 1993;:12:244-246